Mobile Contingency Management for Smoking Cessation
(P3 Trial)
Trial Summary
What is the purpose of this trial?
The purpose of the proposed project is to evaluate an automated mobile phone-based CM approach that will allow socioeconomically disadvantaged individuals to remotely benefit from financial incentives for smoking cessation. The investigators have previously combined technologies including 1) portable carbon monoxide monitors that connect with mobile phones to remotely verify smoking abstinence, 2) facial recognition software to confirm participant identity during breath sample submissions, and 3) remote delivery of incentives automatically triggered by biochemical confirmation of self-reported abstinence. This automated CM approach will be evaluated in a randomized controlled trial that includes 532 socioeconomically disadvantaged males and females seeking smoking cessation treatment. Participants will be randomly assigned to either telephone counseling and nicotine replacement therapy (standard care \[SC\]) or SC plus a mobile financial incentives intervention (CM) for biochemically-confirmed abstinence. Participants will be followed for 26 weeks after a scheduled quit attempt. Biochemically-verified 7-day point prevalence abstinence at 26 weeks post-quit will be the primary outcome variable. Cost-effectiveness will be evaluated to inform policy-related decisions. Potential mobile CM treatment mechanisms, including self-efficacy, motivation, and treatment engagement, will be explored to optimize future versions of the intervention.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, you must be willing to quit smoking and abstain from smoking cannabis and other tobacco products.
What data supports the effectiveness of the treatment Mobile Contingency Management for Smoking Cessation?
Research shows that contingency management (CM), including mobile CM, is effective in helping people quit smoking, especially among those with substance use disorders and difficult-to-treat populations. Studies have found that CM can improve smoking cessation outcomes when combined with other treatments like cognitive-behavioral therapy (CBT) and standard care.12345
Is mobile contingency management for smoking cessation safe for humans?
How is the Mobile Contingency Management treatment for smoking cessation different from other treatments?
Mobile Contingency Management (mCM) is unique because it uses a smartphone app to remotely monitor smoking behavior and deliver rewards for abstinence, making it a low-cost and accessible option compared to traditional in-person methods. This approach is particularly beneficial for populations with limited access to healthcare facilities, such as homeless veterans, and has shown promising results in increasing smoking cessation rates.12357
Research Team
Darla E. Kendzor, PhD
Principal Investigator
University of Oklahoma
Eligibility Criteria
This trial is for adults over 18 who smoke at least 5 cigarettes daily, want to quit within 7-14 days after joining, and earn below a certain income level. They must not use other tobacco products or have conditions that prevent using nicotine replacement therapy (NRT). A valid ID and U.S. residence proof are required.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either standard care with telephone counseling and nicotine replacement therapy or standard care plus a 12-week smartphone-based financial incentives intervention for smoking cessation
Follow-up
Participants are monitored for smoking abstinence and cost-effectiveness for 26 weeks after the scheduled quit attempt
Treatment Details
Interventions
- Automated Mobile Contingency Management (CM)
- Standard Care (SC)
Automated Mobile Contingency Management (CM) is already approved in United States for the following indications:
- Smoking cessation
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Oklahoma
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
M.D. Anderson Cancer Center
Collaborator
H. Lee Moffitt Cancer Center and Research Institute
Collaborator
University of Florida
Collaborator